Genta to Hold Conference Call and Webcast to Discuss Year End and Fourth Quarter 2003 Results
February 06, 2004 12:00:00 PM ET
BERKELEY HEIGHTS, N.J., Feb. 6 /PRNewswire-FirstCall/ -- Genta Incorporated GNTA will host a conference call and live audio webcast of its year end and fourth quarter financial results on Wednesday, February 11, 2004. Dr. Raymond P. Warrell, Jr., Chairman and Chief Executive Officer, and other corporate officers will host the conference call and live audio webcast at 8:00 AM EST.
The conference call can be accessed live as follows:
U.S./Canada: Dial (877) 634-8606, reference Genta Incorporated.
International: Dial (706) 679-3140, reference Genta Incorporated.
The webcast will be available in the Investor Relations section of the Company's website at: genta.com and will be archived for 30 days.
About Genta
Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The Company's research platform is anchored by two major programs that center on oligonucleotides (RNA and DNA-based medicines) and small molecules. Genasense(TM) (oblimersen sodium), the Company's lead compound from its oligonucleotide program, is being developed with Aventis and is currently undergoing late-stage, Phase 3 clinical testing. The leading drug in Genta's small molecule program is Ganite(TM) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of patients with cancer-related hypercalcemia that is resistant to hydration. For more information about Genta, please visit our website at: www.genta.com.
This press release and the conference call and webcast to follow contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report/Form 10-K for 2002.
© 2004 PRNewswire |
